Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Nucleotide-supplemented infant formula

This article was originally published in The Tan Sheet

Executive Summary

Nucleotide-supplemented infant formula: Significantly increases infants' antibody production in response to Haemophilus influenzae type b and diphtheria challenges compared to a non-supplemented formula control group, Larry Pickering, MD, Center for Pediatric Research, Norfolk, Va., et al., report in the February issue of Pediatrics. Iron-fortified/milk-based formula, the same formula fortified with nucleotides, or human milk were given to 311 infants for 12 months, while researchers measured at six, seven and 12 months the infants' production of antibodies in response to a standard routine of immunization shots. Although nucleotides are in all infant formulas, Ross Labs' Improved Similac, which was used in the study, is the only formula sold in the U.S. with a nucleotide content equivalent to breast milk. The Abbott subsidiary funded the study...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088059

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel